Arbutus Biopharma Corp
ABUSHealthcare|Biotechnology|USA
$4.79
-0.34 (-6.52%)
Tangible Book
$1.32
Graham Number
$4.93
Upcoming Data Readouts (2)
Dec 2026
Est. completion
P2Chronic Hepatitis B
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
NCT06154278n=10
Aug 2029
Est. completion
Long Term Follow-up
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
NCT06277037n=50